BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Delpacibart braxlosiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Delpacibart braxlosiran\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07038200-11250@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Delpacibart braxlosiran: Phase 3 readout est. (NCT07038200)
DESCRIPTION:Delpacibart braxlosiran\, phase 3\, Facioscapulohumeral Muscula
 r Dystrophy.\nStudy: A Study to Evaluate Del-brax (Also Referred to as AOC
  1020) in Participants With FSHD\nEstimated primary completion: May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/delpacibart-braxlosir
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7038200
URL:https://assetmemo.bio/drug/delpacibart-braxlosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547216-11250@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Delpacibart braxlosiran: Phase 2 readout est. (NCT06547216)
DESCRIPTION:Delpacibart braxlosiran\, phase 2\, Facioscapulohumeral Muscula
 r Dystrophy.\nStudy: Phase 2 Open-label Extension Study of AOC 1020 in Par
 ticipants With Facioscapulohumeral Muscular Dystrophy (FSHD)\nEstimated pr
 imary completion: April 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/delpacibart-braxlosiran#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06547216
URL:https://assetmemo.bio/drug/delpacibart-braxlosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
